John Johnson Sells 23,693 Shares of AxoGen (NASDAQ:AXGN) Stock

AxoGen, Inc. (NASDAQ:AXGN) Director John Johnson sold 23,693 shares of AxoGen stock in a transaction on Monday, December 8th. The stock was sold at an average price of $31.24, for a total value of $740,169.32. Following the completion of the transaction, the director owned 13,141 shares in the company, valued at $410,524.84. The trade was a 64.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

John Johnson also recently made the following trade(s):

• On Tuesday, December 9th, John Johnson sold 21,686 shares of AxoGen stock. The shares were sold at an average price of $29.98, for a total transaction of $650,146.28.

AxoGen Stock Down 2.0%

NASDAQ:AXGN traded down $0.60 during trading hours on Wednesday, hitting $30.01. 679,926 shares of the stock traded hands, compared to its average volume of 854,756. The firm has a 50 day moving average price of $22.57 and a 200 day moving average price of $16.58. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -600.20 and a beta of 1.06. AxoGen, Inc. has a fifty-two week low of $9.22 and a fifty-two week high of $34.24. The company has a current ratio of 4.09, a quick ratio of 2.64 and a debt-to-equity ratio of 0.54.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.03. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%.The firm had revenue of $60.08 million during the quarter, compared to the consensus estimate of $56.90 million. Equities research analysts anticipate that AxoGen, Inc. will post -0.29 earnings per share for the current year.

Hedge Funds Weigh In On AxoGen

Large investors have recently modified their holdings of the stock. Future Financial Wealth Managment LLC acquired a new stake in shares of AxoGen during the third quarter worth $27,000. Aquatic Capital Management LLC increased its position in AxoGen by 287.8% during the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 1,269 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of AxoGen during the 3rd quarter valued at $43,000. Tower Research Capital LLC TRC increased its stake in AxoGen by 189.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 3,327 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in AxoGen by 882.2% during the 2nd quarter. AlphaQuest LLC now owns 6,276 shares of the medical equipment provider’s stock valued at $68,000 after acquiring an additional 5,637 shares in the last quarter. 80.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AXGN. Weiss Ratings restated a “sell (e+)” rating on shares of AxoGen in a report on Monday. Canaccord Genuity Group upped their target price on AxoGen from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Raymond James Financial reiterated an “outperform” rating and issued a $36.00 price target on shares of AxoGen in a research report on Thursday, December 4th. Mizuho assumed coverage on shares of AxoGen in a research report on Monday, December 1st. They set an “outperform” rating and a $40.00 price target on the stock. Finally, HC Wainwright raised their target price on shares of AxoGen from $26.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.56.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.